933 related articles for article (PubMed ID: 27382030)
1. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
[TBL] [Abstract][Full Text] [Related]
2. Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
Keizman D; Rouvinov K; Sella A; Gottfried M; Maimon N; Kim JJ; Eisenberger MA; Sinibaldi V; Peer A; Carducci MA; Mermershtain W; Leibowitz-Amit R; Weitzen R; Berger R
Cancer Res Treat; 2016 Jan; 48(1):281-7. PubMed ID: 25761478
[TBL] [Abstract][Full Text] [Related]
3. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
5. Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
Keizman D; Ish-Shalom M; Sella A; Gottfried M; Maimon N; Peer A; Hammers H; Eisenberger MA; Sinibaldi V; Neiman V; Rosenbaum E; Sarid D; Mermershtain W; Rouvinov K; Berger R; Carducci MA
Clin Genitourin Cancer; 2016 Oct; 14(5):420-425. PubMed ID: 27211307
[TBL] [Abstract][Full Text] [Related]
6. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib.
Keizman D; Gottfried M; Ish-Shalom M; Maimon N; Peer A; Neumann A; Hammers H; Eisenberger MA; Sinibaldi V; Pili R; Hayat H; Kovel S; Sella A; Boursi B; Weitzen R; Mermershtain W; Rouvinov K; Berger R; Carducci MA
Oncologist; 2014 Jan; 19(1):51-60. PubMed ID: 24309979
[TBL] [Abstract][Full Text] [Related]
7. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
Keizman D; Ish-Shalom M; Pili R; Hammers H; Eisenberger MA; Sinibaldi V; Boursi B; Maimon N; Gottfried M; Hayat H; Peer A; Kovel S; Sella A; Berger R; Carducci MA
Eur J Cancer; 2012 May; 48(7):1031-7. PubMed ID: 22409947
[TBL] [Abstract][Full Text] [Related]
9. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Lolli C; Basso U; Derosa L; Scarpi E; Sava T; Santoni M; Crabb SJ; Massari F; Aieta M; Conteduca V; Maruzzo M; La Russa F; Wheater M; Berardi R; Galli L; De Giorgi U
Oncotarget; 2016 Aug; 7(34):54564-54571. PubMed ID: 27409344
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Yildiz I; Ekenel M; Akman T; Kocar M; Uysal M; Kanitez M; Varol U; Bayoglu IV; Tural D; Kaplan MA; Avci N; Sürmeli Z; Dede İ; Ulaş A; Yazici O; Basaran M
Anticancer Res; 2014 Aug; 34(8):4329-34. PubMed ID: 25075067
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
12. Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.
Elfiky AA; Cho DC; McDermott DF; Rosenberg JE; Fortner B; Antràs L; Chen K; Sheng Duh M; Jayawant SS; Oh WK; Atkins MB; Choueiri TK
Urol Oncol; 2011; 29(6):756-63. PubMed ID: 20451414
[TBL] [Abstract][Full Text] [Related]
13. Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
Beuselinck B; Vano YA; Oudard S; Wolter P; De Smet R; Depoorter L; Teghom C; Karadimou A; Zucman-Rossi J; Debruyne PR; Van Poppel H; Joniau S; Lerut E; Strijbos M; Dumez H; Paridaens R; Van Calster B; Schöffski P
BJU Int; 2014 Jul; 114(1):81-9. PubMed ID: 24215209
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
15. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
[TBL] [Abstract][Full Text] [Related]
16. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
18. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive radiofrequency ablation in patients with metastatic renal cell carcinoma (RCC) with small primary tumours treated with sunitinib or interferon-α.
Tsimafeyeu I; Zart JS; Chung B
BJU Int; 2013 Jul; 112(1):32-8. PubMed ID: 23746142
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.
van der Veldt AA; Eechoute K; Gelderblom H; Gietema J; Guchelaar HJ; van Erp NP; van den Eertwegh AJ; Haanen JB; Mathijssen RH; Wessels JA
Clin Cancer Res; 2011 Feb; 17(3):620-9. PubMed ID: 21097692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]